LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) (LOC-R01)

  • End date
    Jan 15, 2031
  • participants needed
  • sponsor
    Institut Curie
Updated on 28 April 2022
measurable disease
cell transplantation
gilbert's syndrome
neutrophil count
b-cell lymphoma


This study is to improve the first-line induction chemotherapy, by combining either Ibrutinib, or Lenalidomide, to a conventional immuno- chemotherapy of R-MPV type (Rituximab-Methotrexate-Procarbazine-Vincristine). This is a randomized Phase II trial, preceded by a dose escalation phase Ib. The objective of the phase Ib is to rule out any limiting toxicity of the new treatment associations, and to determine the recommended dose of Lenalidomide and Ibrutinib to be used in the phase II. In the phase II study, patients will receive 4 cycles of R-MPV + Lenalidomide or 4 cycles of R-MPV + Ibrutinib. The therapeutic response will be evaluated after the 2nd and the 4th cycle. Patients in good therapeutic response will proceed to the consolidation phase with Autologous Stem Cell Transplantation (ASCT).


The objective of this proposal is to test the feasibility and efficacy of two targeted induction chemotherapies obtained by adding either Lenalidomide or Ibrutinib to a standard Rituximab-High Dose (HD) Methotrexate (MTX) based induction chemotherapy regimen. The R-MPV regimen is chosen as the backbone chemotherapy because of its wide use with robust reproducible results and a good and manageable toxicity profile

Condition Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Primary
Treatment Ibrutinib, Lenalidomide
Clinical Study IdentifierNCT04446962
SponsorInstitut Curie
Last Modified on28 April 2022


Yes No Not Sure

Inclusion Criteria

Newly diagnosed Primary Central Nervous System Lymphoma (PCNSL)
a) Aged between 18 and 60 (>18 and < 60) - phase IB b) Aged between 18 and 65 (≥ 18 and ≤ 65) - phase II
Histological confirmed diagnosis of Primary central nervous system lymphoma of Diffuse Large B-Cell Lymphomas (DLBCL) type OR patients with a measurable typical cerebral lesion on MRI with a diagnosis made by cytology and/or by flow cytometry on the vitreous or on the cerebral spinal fluid
Measurable lesion on MRI with gadolinium enhancement
Adequate hematological, renal and hepatic function (Laboratory Parameters realized within 14 days before inclusion)
Absolute neutrophil count (ANC) >1000/mm3
Platelets > 100,000/mm3 independent of transfusion support
Alanine aminotransferase and aspartate aminotransferase ≤ 3 x Upper Limit of Normal (ULN)
Total bilirubin ≤ 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin
Estimated Glomerular Filtration Rate ≥ 60 mL/min/1.73m2
Able to swallow capsules
Karnofsky performance status: 40-100% for the phase IB and no restriction on the KPS for the phase II
Able to understand teratogenic risks of the Lenalidomide and Ibrutinib. Patient must be able to understand and fulfill the Lenalidomide Pregnancy Prevention Plan requirements. This plan may be accepted by the person of confidence in case of impaired cognitive status of the patient
Women of childbearing potential (WCBP) _and men who are sexually active must be practicing a highly effective method_ of birth control. Women should avoid a pregnancy while taking treatment by Lenalidomide or Ibrutinib and for up to 1 month after ending treatment. Men must agree to not to father a child or donate sperm during treatment by Lenalidomide or Ibrutinib and up to 3 months after the last dose of study drug
Women of childbearing potential (WCBP) must have a negative serum (beta-human chorionic gonadotropin [B-hCG]) or urine pregnancy test at inclusion
Signed informed consent, which could be signed by a person on confidence in case the neurologic status of the patient does not allow him to understand and/or to sign

Exclusion Criteria

Histology other than DLBCL
Positive HIV serology
Active viral infection with Hepatitis B or C virus
Preexisting immunodeficiency and/or organ transplant recipient
Isolated Central Nervous System (CNS) relapse of systemic Non-Hodgkin's Lymphoma
Prior treatment for PCNSL (except corticosteroids)
Isolated primary vitreo-retinal lymphoma
Major surgery, within 4 weeks prior to the first dose of study drug. Stereotactic biopsy and vitrectomy are not considered major surgery
History of stroke or intracranial hemorrhage (except minor post biopsy hemorrhage) within 6 months prior to inclusion
Requires anticoagulation with warfarin or equivalent vitamin K antagonists
Requires treatment with strong CYP3A4 inhibitors
Pregnancy or lactation
Clinically significant cardiovascular disease
Any other active malignancy, except basocellular carcinoma and non-invasive cervix cancer
Inclusion in another experimental anti-cancer drug therapy
No social security affiliation
Persons under legal protection
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note